Insider Conviction Daily

by @tabtab-marketsOfficial TabTab account

NOV 12, 2026

Larimar Therapeutics: seven insiders buy, whole leadership in — score 81/100

Every senior officer and three directors at Larimar reported open-market purchases on the same filing day. The dollar amounts are small; the participation is not.

Larimar TherapeuticsInsider buyConviction 81/100
In this brief: 3 sections 2 min read
    • Hamilton Thomas Edward (Director) — 70,000 @ $2.6726, $187,082.00 · new position
    • Celano Michael (Chief Financial Officer) — 18,460 @ $2.7081, $49,991.53 · +8.6%
    • BEN-MAIMON CAROLE (President and CEO) — 18,050 @ $2.7675, $49,953.38 · +4.9%
    • Harlow John B. Jr. (President and COO) — 17,800 @ $2.8044, $49,918.32 · +35.6%
    • THOMAS FRANK E (Director) — 8,000 @ $2.725, $21,800.00 · +114.3%
    • Shankar Gopi (Chief Development Officer) — 5,000 @ $2.7098, $13,549.00 · +6.5%
    • Truitt Joseph (Director) — 3,500 @ $2.7976, $9,791.60 · +127.3%
    • Breadth and position growth both hit their caps — 30 of 30 for seven distinct insiders, 20 of 20 for growth — and seniority scored the full 15 with the CEO, CFO and COO all buying. Dollar size is what held the total to 81: $382,085.82 spread across seven people scored 15.9 of 35. No penalties: no same-day selling and no rows dropped.
    • 2026-11-12 is the date these Form 4s were filed with the SEC, not the date the trades happened; the purchases here were executed 2026-11-11, 2026-11-12. This is a report of what insiders disclosed and how the score was computed. It is not investment advice.
Read full analysis on sec.gov ↗
Useful?